Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Chemother Pharmacol ; 56(4): 337-43, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15895232

RESUMO

Recently, we reported a new class of DNA-targeted hybrid platinum-acridine agents. The parent intercalator, ACRAMTU, a 9-aminoacridine derivative, intercalates into the minor groove of DNA, causing the corresponding prototypical conjugate, PT-ACRAMTU (type I/n=2), to form DNA adducts dissimilar to traditional platinum drugs. Both these agents show cytotoxic activity in leukemic and ovarian cancer cells. Following the use of clonogenic survival assays, we report on the cytotoxic effects of ACRAMTU, PT-ACRAMTU, and three PT-ACRAMTU derivatives, on additional cell lines including colon (RKO), lung (H460), and cisplatin-sensitive (A2780) and cisplatin-resistant (A2780/CP) ovarian cells. While a dose-dependent effect was observed with both ACRAMTU and PT-ACRAMTU, an enhanced cytotoxic effect was seen with PT-ACRAMTU in all cell lines. PT-ACRAMTU appeared to have a similar IC50 value to cisplatin except in H460 lung cancer cells in which PT-ACRAMTU had a twofold lower IC50 value. PT-ACRAMTU appeared to act in a time-dependent manner. In H460 cells the IC50 value of PT-ACRAMTU was 235-fold higher following a 1-h incubation than following a 24-h incubation (0.27 microM), while following an 8-h incubation the IC50 value was 0.41 microM. Three derivatives of PT-ACRAMTU were also tested. A tetraalkylated derivative, type II/n=2, generated the highest IC50 values in all cell lines, while the trialkylated derivative, type III/n=2, generated IC50 values similar to its isomer, PT-ACRAMTU. PT-ACRAMTU with an added CH2 group in the thiourea linker (type I/n=3) showed IC50 values similar to the type I/n=2 prototype in H460 lung cells. An apoptotic response to PT-ACRAMTU appeared to be generated in H460 cells as evidenced by DNA laddering. These results suggest that type I/n=2 and type I/n=3 may be promising agents for the treatment of lung cancer and should be pursued in animal models.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Apoptose/efeitos dos fármacos , Cisplatino/uso terapêutico , Adutos de DNA/efeitos dos fármacos , Neoplasias Pulmonares/tratamento farmacológico , Platina/uso terapêutico , Ureia/análogos & derivados , Linhagem Celular Tumoral , Humanos , Neoplasias Pulmonares/radioterapia , Ureia/uso terapêutico
2.
Bioorg Med Chem Lett ; 13(5): 855-8, 2003 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-12617907

RESUMO

The preparation of two novel bis(acridine)platinum(II) complexes is reported. The 4+ charged conjugates associate strongly with double-stranded native DNA (K(i)>10(6)), possibly through bisintercalation. A cell viability assay was used to demonstrate that both compounds are capable of mediating cytotoxicity at micromolar concentrations in SNB19 brain tumor cells.


Assuntos
Acridinas/química , Acridinas/farmacologia , Antineoplásicos/síntese química , Antineoplásicos/farmacologia , DNA/química , Glioblastoma/tratamento farmacológico , Compostos Organoplatínicos/síntese química , Compostos Organoplatínicos/farmacologia , Acridinas/metabolismo , Animais , Bovinos , Sobrevivência Celular/efeitos dos fármacos , DNA/metabolismo , Humanos , Substâncias Intercalantes/síntese química , Substâncias Intercalantes/farmacologia , Compostos Organoplatínicos/metabolismo , Espectrofotometria Ultravioleta , Tioureia/análogos & derivados , Tioureia/farmacologia , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...